Philip Pitis
Publications by Year
Research Areas
Pharmacological Receptor Mechanisms and Effects, Chromatin Remodeling and Cancer, Neuropeptides and Animal Physiology, Receptor Mechanisms and Signaling, Peptidase Inhibition and Analysis
Most-Cited Works
- → A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine(2013)639 cited
- → Structure–Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain(2013)196 cited
- → Aroyl(aminoacyl)pyrroles, a New Class of Anticonvulsant Agents(1997)57 cited
- → Parallel methods for the preparation and SAR exploration of N-ethyl-4-[(8-alkyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-aryl-methyl]-benzamides, powerful mu and delta opioid agonists(2004)28 cited
- → N , N -Dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective δ opioid agonists(2004)19 cited
- → The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216(2006)15 cited
- → Abstract 3263: Preclinical characterization of PRT3789, a potent and selective SMARCA2 targeted degrader(2022)10 cited
- → N -Alkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, μ and δ opioid agonists: a μ address(2004)6 cited
- → Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers(2023)3 cited
- → Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2(2024)2 cited